Eating Disorders

Overview of Eating Disorders
Eating disorders are serious psychiatric disorders characterized by abnormal eating or weight-control behaviors. Disturbing attitudes towards weight, body shape, and eating play a key role in their origin and maintenance. The form of these concerns varies by gender; in men, for example, body image concerns might focus on muscularity, whereas in women, these concerns might focus more on weight loss. Obesity per se is not framed as an eating disorder. All eating disorders considerably impair physical health and disrupt psychosocial functioning. Both the diagnostic and statistical manual (DSM-5) and the international classification of diseases (ICD-11) encompass six main feeding and eating disorders. These include the familiar diagnostic categories of anorexia nervosa, bulimia nervosa, and binge eating disorder. In addition, three disorders previously mainly viewed as childhood disorders have been included. These are avoidant-restrictive food intake disorder, pica, and rumination disorder. DSM-5 also provides subtype qualifiers, severity indicators, and definitions of remission.
Aetiology of Eating Disorders
Aetiology diagram of restrictive-type eating disorders
Biological factors
|
|
Psychological factors
|
|
Psychosocial factors
|
Behavioral factors
|
Aetiology diagram of bulimic spectrum eating disorders
Biological factors
|
|
Psychological factors
|
|
Psychosocial factors
|
Behavioral factors
|
Treatment of Eating Disorders
Early intervention improves outcomes; therefore, rapid commencement of specialized eating disorder treatment and care rather than watchful waiting is essential. For mild or moderately severe cases, the first step is an outpatient psychological treatment involving family members in an age-appropriate manner. If the medical or psychological risk is high or there is an irresponsiveness to outpatient care, then the greater intensity of care can be provided by outreach, day, or inpatient facilities. Studies in the UK National Health Service suggest that about 20-35% of patients will need this higher level of care. There is uncertainty about the management of patients who continue to be symptomatic following these first-line treatments, although recovery remains possible for more than 60% of patients even after 20 years. Patients often request that their families and treatment teams should not give up on them. New forms of treatments are being considered for this group, but some aspects of management are controversial. Transitions between services for age, educational, or physical reasons need to be carefully managed.
Trend of Research
Over the past 50 years and in the context of major changes in our environment, eating disorders have evolved into a variety of forms with overlapping and distinct clinical and aetiological features, affecting people of all ages and social classes. The prevalence of eating disorders is moderately high, although most affected individuals do not present for treatment. Lengthy periods of untreated symptoms can lead to an entrenched form of illness, which is more difficult to treat. In brief, advances are needed to allow more precise elucidation of the mechanisms that underpin these problems and to develop more targeted treatments. At the same time, disseminable and scalable treatments are needed.
Eating Disorders Related Products at Creative Biolabs
Target | Product Name | Cat# |
Dopamine | Dihydroergotamine mesylate [α-adrenoceptor; 5-HT; Dopamine D2 Receptor Antagonist | MOD2005ZP208 |
Dopamine | 6-Hydroxydopamine (6-OHDA) hydrobromide [Dopamine Neurotoxin] | MOD2005ZP215 |
Dopamine | ABT 724 trihydrochloride [Dopamine D4 Receptor Agonist] | MOD2005ZP216 |
Dopamine | Amisulpride [Dopamine D2 Receptor; Dopamine D3 Receptor Antagonist] | MOD2005ZP217 |
Dopamine | Dihydroergocristine mesylate [5-HT; Adenosine Receptor; Dopamine Receptor; γ-secretase Antagonist] | MOD2005ZP221 |
Oxytocin | Oxytocin [Reproductive hormone] | MOD2005ZP776 |
Oxytocin | Oxytocin (free acid) [Reproductive hormone] | MOD2005ZP783 |
Oxytocin | Human Oxytocin Prepropeptide ELISA Kit [Colorimetric] | NPP2011ZP160 |
Oxytocin | Human Oxytocin ELISA Kit [Colorimetric] | NPP2011ZP161 |
Oxytocin | Human Oxytocin Antibody Pair, BSA and Azide Free [Colorimetric] | NPP2011ZP162 |
Oxytocin | rAAV-Oxytocin-CRE-WPREs | NTA-2010-TT308 |
Oxytocin | Oxytocin Peptide | NPP2012411CR |
Oxytocin | Human Recombinant Oxytocin Receptor Stable Cell Line | NCL20120134CR |
Oxytocin | Rabbit Oxytocin Antibody | NAB-2102-MP22 |
If you are working on eating disorders and need any assistance, or you have any other questions about our services, please don’t hesitate to contact us for more information.
- iNeuMab™ Rabbit Anti-Alpha-synuclein (CBP1631) (Cat#: NAB-08-PZ079)
- iNeuMab™ Anti-pTau Antibody (NRP-0422-P1719) (Cat#: NRP-0422-P1719)
- iNeuMab™ Anti-Tau Antibody (NRP-0422-P1683) (Cat#: NRP-0422-P1683)
- iNeuMab™ Anti-Tau Antibody (NRP-0422-P1686) (Cat#: NRP-0422-P1686)
- iNeuMab™ Anti-GARP Antibody (NRP-0422-P1639) (Cat#: NRP-0422-P1639)
- iNeuMab™ Anti-F-Spondin/SPON1 Antibody, Clone 3F4 (Cat#: NRZP-0822-ZP4740)
- iNeuMab™ Anti-SEZ6 Antibody (NRP-0422-P515) (Cat#: NRP-0422-P515)
- iNeuMab™ Anti-TREM2 Antibody (NRP-0422-P792) (Cat#: NRP-0422-P792)
- iNeuMab™ Anti-CD20 Antibody (NRP-0422-P1230) (Cat#: NRP-0422-P1230)
- iNeuMab™ Anti-Tau Antibody (NRP-0422-P1760) (Cat#: NRP-0422-P1760)
- Green Fluorescent BACE1 Cell Lines (Cat#: NCL2110P214)
- Rat Schwann Cells RSC96, Immortalized (Cat#: NCL-2108P21)
- Human Neurons Isolated from Cortex (Cat#: NCL-21P6-023)
- Human Dental Pulp Stem Cells (Cat#: NRZP-1122-ZP113)
- iNeu™ Human Oligodendrocyte Progenitor Cells (OPCs) (Cat#: NCL-2103-P49)
- Mouse Midbrain Dopaminergic Neuron Cell MN9D (Cat#: NCL2110P059)
- Mouse Microglia N9 (Cat#: NCL2110P073)
- Mouse Retinal Ganglion Cell Line RGC-5 (Cat#: NCL2110P154)
- Human Glial (Oligodendrocytic) Hybrid Cell Line (MO3.13) (Cat#: NCL-2108P34)
- Immortalized Human Cerebral Microvascular Endothelial Cells (Cat#: NCL-2108-P020)
- Beta Amyloid (1-40), Aggregation Kit (Cat#: NRZP-0323-ZP199)
- Human GFAP ELISA Kit [Colorimetric] (Cat#: NPP2011ZP383)
- Alpha Synuclein Aggregation Kit (Cat#: NRZP-1122-ZP15)
- Human Tau Aggregation Kit (Cat#: NRP-0322-P2173)
- Alpha-Synuclein Aggregation Assay Kit (Cat#: NRZP-1122-ZP37)
- Amyloid beta 1-42 Kit (Cat#: NRP-0322-P2170)
- Human Poly ADP ribose polymerase,PARP Assay Kit (Cat#: NRZP-1122-ZP62)
- Beta Amyloid (1-42), Aggregation Kit (Cat#: NRZP-0323-ZP200)
- Dextran, NHS Activated (Cat#: NRZP-0722-ZP124)
- AAV2/9-hEF1a-fDIO-eNpHR 3.0-mCherry-WPRE-pA (Cat#: NTA-2012-ZP78)
- VSV-eGFP (Cat#: NTA-2011-ZP20)
- AAV2 Full Capsids, Reference Standards (Cat#: NTC2101070CR)
- Human presenilin 1 (PSEN1), transcript variant 2 (NM_007318) ORF clone, TurboGFP Tagged (Cat#: NEP-0421-R0140)
- Lenti of Human TAR DNA binding protein (TARDBP) (NM_007375) ORF clone, mGFP Tagged (Cat#: NEP-0521-R0832)
- Human superoxide dismutase 1, soluble (SOD1) (NM_000454) ORF clone, TurboGFP Tagged (Cat#: NEP-0521-R0748)
- Human apolipoprotein E (APOE) (NM_000041) ORF clone, Untagged (Cat#: NEP-0421-R0232)
- Human huntingtin-associated protein 1 (HAP1) transcript variant 2 (NM_177977) ORF clone, Myc-DDK Tagged (Cat#: NEP-0521-R0676)
- Mouse Parkinson disease (autosomal recessive, early onset) 7 (Park7) (NM_020569) clone, Untagged (Cat#: NEP-0621-R0133)
- Human superoxide dismutase 3, extracellular (SOD3) (NM_003102) ORF clone, Untagged (Cat#: NEP-0521-R0808)
- Tau Antisense Oligonucleotide (IONIS-MAPTRx) (Cat#: NV-2106-P29)
- Human huntingtin (HTT) (NM_002111) ORF clone, Myc-DDK Tagged (Cat#: NEP-0521-R0497)
- Lenti of Mouse synuclein, alpha (Snca) transcript variant (NM_001042451) ORF clone, mGFP Tagged (Cat#: NEP-0521-R0864)
- NeuroBiologics™ Pig Cerebrospinal Fluid (Cat#: NRZP-0822-ZP498)
- NeuroBiologics™ Human Cerebrospinal Fluid (Cat#: NRZP-0822-ZP491)
- NeuroBiologics™ Monkey Cerebrospinal Fluid (Cat#: NRZP-0822-ZP495)
- NeuroBiologics™ Rat Cerebrospinal Fluid (Cat#: NRZP-0822-ZP496)
- NeuroBiologics™ Mouse Cerebrospinal Fluid (Cat#: NRZP-0822-ZP497)
- NeuroPro™ Anti-IDS BBB Shuttle Protein (Cat#: NRZP-0423-ZP503)
- NeuroPro™ Anti-GDNF BBB Shuttle Protein (Cat#: NRZP-0423-ZP509)
- NeuroPro™ Anti-PON1 BBB Shuttle Protein (Cat#: NRZP-0423-ZP507)
- NeuroPro™ Anti-GDNF BBB Shuttle Protein (Cat#: NRZP-0423-ZP500)
- NeuroPro™ Anti-EPO BBB Shuttle Protein (Cat#: NRZP-0423-ZP508)
- NeuroPro™ Anti-TNFR BBB Shuttle Protein (Cat#: NRZP-0423-ZP510)
- NeuroPro™ Anti-NAGLU BBB Shuttle Protein (Cat#: NRZP-0423-ZP506)
- NeuroPro™ Anti-TNFR BBB Shuttle Protein (Cat#: NRZP-0423-ZP501)
- NeuroPro™ Anti-idursulfase BBB Shuttle Protein (Cat#: NRZP-0423-ZP497)
- NeuroPro™ Anti-IDUA BBB Shuttle Protein (Cat#: NRZP-0423-ZP502)